Taiho Pharmaceutical Co Sustainability Profile
Taiho Pharmaceutical Co., Ltd., commonly referred to as Taiho, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in 1963, the company has made significant strides in oncology, urology, and other therapeutic areas, positioning itself as a leader in innovative drug development. With a strong operational presence in Japan and expanding markets across Asia and the United States, Taiho is renowned for its commitment to research and development. The company’s core products, including anti-cancer agents and supportive care medications, are distinguished by their efficacy and safety profiles. Taiho's dedication to advancing healthcare has earned it notable achievements, including partnerships with global pharmaceutical firms and recognition for its contributions to cancer treatment. As it continues to grow, Taiho remains focused on delivering high-quality healthcare solutions that meet the evolving needs of patients worldwide.
DitchCarbon Score
How does Taiho Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Taiho Pharmaceutical Co's score of 56 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Taiho Pharmaceutical Co., Ltd., headquartered in Japan, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas (GHG) emissions. The company has pledged to reduce its absolute Scope 1 and Scope 2 GHG emissions by 30% by the year 2030, using 2017 as the baseline year. Additionally, Taiho Pharmaceutical aims to achieve a 20% reduction in its absolute Scope 3 emissions by the same year. These targets are aligned with the Science Based Targets initiative (SBTi) and are classified as consistent with the reductions necessary to limit global warming to 2°C. The commitments reflect Taiho Pharmaceutical's proactive approach to addressing climate change and its responsibility within the pharmaceutical industry. As of now, there is no specific emissions data available for Taiho Pharmaceutical, indicating a potential area for improvement in transparency regarding their current carbon footprint. The company's initiatives are cascaded from its parent organization, Otsuka Holdings Co., Ltd., which further underscores its commitment to sustainability within the corporate family structure.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 101,000,000 | - | - | - | - | 000,000,000 | - | - |
| Scope 2 | 159,000,000 | - | - | - | - | 0,000,000 | - | - |
| Scope 3 | 866,000,000 | - | - | - | 000,000,000 | - | - | - |
How Carbon Intensive is Taiho Pharmaceutical Co's Industry?
How Carbon Intensive is Taiho Pharmaceutical Co's Location?
Taiho Pharmaceutical Co's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Taiho Pharmaceutical Co has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
